Dr. Mark Opler, PhD, MPH | Chief Research Officer

Dr. Mark Opler serves as Chief Research Officer, directing scientific research and development at MedAvante-ProPhase. Dr. Opler was the founder of ProPhase and served as its CEO and Chief Scientific Officer among other positions. He holds the titles of Adjunct Assistant Professor of Psychiatry at New York University and Assistant Professor of Clinical Neuroscience at Columbia University’s College of Physicians and Surgeons. His academic research focuses on the etiology, phenomenology, and treatment of serious and persistent mental disorders. He is also leading the development of the new upcoming edition of the PANSS Manual©.

  • The State of Clinical Trials in Autism and Neurodevelopmental Disorders with Dr. Scott Hunter

    The State of Clinical Trials in Autism and Neurodevelopmental Disorders with Dr. Scott Hunter

    Podcast
  • Protecting Sponsors Against Bias and Variability

    Protecting Sponsors Against Bias and Variability

    Applied Clinical Trials recently spoke with Mark Opler, PhD, MPH, chief research officer of WCG, MedAvante-ProPhase, to learn why placebo response is the leading cause of failed trials.

    Read Flipbook
  • Interview with Dr. Andrew Cutler25:31

    Interview with Dr. Andrew Cutler

    Dr. Cutler shares his insights on the current challenges and opportunities for CNS therapies and clinical trials during an energizing conversation with Dr. Mark Opler.

    Watch Video
  • Effect of parental age on treatment response in adolescents with schizophrenia

    Effect of parental age on treatment response in adolescents with schizophrenia

    Read Flipbook
  • Using PANSS Score Profiles to Predict Early Termination in a Study on Acute Exacerbation of Schizophrenia

    Using PANSS Score Profiles to Predict Early Termination in a Study on Acute Exacerbation of Schizophrenia

    Blinded analyses were aimed to determine how different atypical Positive and Negative Syndrome Scale (PANSS) score profiles (identified using algorithms) were able to predict early termination.

    Read Flipbook
  • The brief negative symptom scale (BNSS): Sensitivity to treatment effects

    The brief negative symptom scale (BNSS): Sensitivity to treatment effects

    Read Flipbook
  • Using scoring algorithms to identify serious scoring violations among placebo responders and non-responders in clinical trials using the Pos

    Using scoring algorithms to identify serious scoring violations among placebo responders and non-responders in clinical trials using the Pos

    The objective was to use a priori scoring algorithm designed to assess violations and non-violations on PANSS items.

    Read Flipbook
  • Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia

    Bridging the Measurement Gap Between Research and Clinical Care in Schizophrenia

    The aim of this paper is to discuss how the measurement gap between research and clinical care in schizophrenia can be closed.

    Read Flipbook
  • A Developmental History of the Positive and Negative Syndrome Scale (PANSS)

    A Developmental History of the Positive and Negative Syndrome Scale (PANSS)

    In this review article, the authors explore the history of the most influential schizophrenia research tools that have been created over the past several decades.

    Read Flipbook
  • Placebo Response in Clinical Trials: Approaches to Mitigation58:43

    Placebo Response in Clinical Trials: Approaches to Mitigation

    Industry trends show that a major contributor to trial failure is the increased rate of placebo response.Watch this webinar to learn how to increase the chances of trial success in an uncertain world.

    Watch Video
  • Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions

    Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions

    In this article, the authors review the methods for ensuring reliability of the PANSS as well as a proposed trajectory for its use in the future.

    Read Flipbook
  • loading
    Loading More...